A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice

scientific article published in January 2003

A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S10120-003-0230-Y
P698PubMed publication ID12775018
P5875ResearchGate publication ID10735847

P2093author name stringYutaka Kimura
Yasuto Naoi
Takeshi Kato
Takahiko Tanigawa
Taro Hayashi
Eiji Kurokawa
Hitoshi Yamamoto
Nobuteru Kikkawa
Shohei Iijima
P2860cites workNew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaQ27860904
Clinical implications of dihydropyrimidine dehydrogenase inhibition.Q33708379
Report on nationwide pooled data and cohort investigation in UFT phase II study.Q36433925
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude ratsQ41196248
A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program StudyQ44583571
Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomasQ67274828
Continuous 5-Fluorouracil Infusion in Advanced Gastric CarcinomaQ68480479
Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracilQ69975754
[Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study]Q69976405
Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extractsQ70355508
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsQ71665880
Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in ratsQ72092575
An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study GroupQ73143101
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patientsQ77809280
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drugQ78206833
P407language of work or nameEnglishQ1860
P304page(s)34-39
P577publication date2003-01-01
P1433published inGastric CancerQ15724608
P1476titleA new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice
P478volume6 Suppl 1